Atrion (NASDAQ:ATRI) Lowered to Sell at StockNews.com

StockNews.com cut shares of Atrion (NASDAQ:ATRI) from a hold rating to a sell rating in a research note issued to investors on Monday.

Atrion Price Performance

Atrion stock opened at $399.83 on Monday. The firm has a 50 day simple moving average of $401.31 and a 200-day simple moving average of $364.59. The stock has a market capitalization of $703.70 million, a PE ratio of 36.25 and a beta of 0.60. Atrion has a 12-month low of $274.98 and a 12-month high of $643.48.

Atrion (NASDAQ:ATRI) last released its earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 EPS for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%. The business had revenue of $43.58 million during the quarter.

Atrion Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 15th were paid a $2.20 dividend. This represents a $8.80 dividend on an annualized basis and a yield of 2.20%. The ex-dividend date of this dividend was Thursday, March 14th. Atrion’s dividend payout ratio is 79.78%.

Hedge Funds Weigh In On Atrion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Copeland Capital Management LLC boosted its stake in shares of Atrion by 56.4% during the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 31 shares during the period. Quadrant Capital Group LLC acquired a new stake in shares of Atrion during the 4th quarter valued at $36,000. Harbor Investment Advisory LLC boosted its stake in shares of Atrion by 33.1% during the 4th quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock valued at $72,000 after buying an additional 47 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Atrion by 592.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 231 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Atrion during the 4th quarter valued at $108,000. Institutional investors and hedge funds own 66.19% of the company’s stock.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.